News Updates
Early treatment of child obesity found effective
The early treatment of obesity in children is effective in both the short and long term, researchers from Karolinska Institutet report in a study published in The International Journal of Obesity.
Tirzepatide more effective in blood sugar control and body weight loss than semaglutide, shows meta-analysis
A new meta-analysis combining 22 studies, to be presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2–6 October), shows that tirzepatide is superior to semaglutide for both control of blood sugar and in terms of amount of body weight lost by patients.
Study links obesity and poor sleep
A new study has found people who sleep badly are also more likely to be obese.
Study shows reduced risk of hematological cancer after bariatric surgery
Obesity surgery is associated with a 40% lower risk of hematological cancer.
Very few children with obesity transition to a healthy weight, finds study
More children with overweight move to a healthier weight over two years than do children with obesity, according to a study published online Sept. 20 in PLOS ONE.
Obesity impairs the brain's response to nutrients, suggests study
Our findings suggest that long-lasting brain adaptations occur in individuals with obesity, which could affect eating behavior.
No increase in mortality for most overweight people, study finds
The prevalence of overweight and obesity has risen dramatically over the last 25 years, and it is well-established that elevated BMI can contribute to several cardio-metabolic conditions.
Teens with severe obesity are turning to surgery and new weight loss drugs
Eighty percent of adolescents with excess weight carry it into adulthood, with potentially dire consequences for their health and longevity.
Higher doses of oral semaglutide improves blood sugar control and weight loss
Higher doses of oral semaglutide improves blood sugar control and weight loss
New drugs line up to challenge Ozempic, Wegovy for weight loss
Lilly's experimental drug orforglipron comes from the blockbuster class of diabetes/weight-loss meds called glucagon-like peptide-1 agonists (GLP-1 agonists) that include Ozempic and Wegovy.